EP0152699A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
An antithrombogenic polyurethane polymer and a process for imparting antithrombogenic activity to a polyurethane substrate
Assignee: Deseret Medical Inc
•
Filing: 1984-12-21
•
Granted: —
•
Expires: 2004-12-21
Abstract
Abstract There is disclosed an antithrombogenic polyurethane polymer which comprises: a polyurethane substrate; a polymeric amine covalently bonded to the polyurethane substrate; and an antithrombogenic agent wherein the polymeric amine is chosen from: a polyvinyl amine, a polyalkylenimine which has 2, 3 or 4 carbon atoms per amine unit, and mixtures thereof. A process for imparting antithrombogenic activity to a polyurethane substrate is also disclosed.
Inventors
- 👤 Donald D. Solomon
- 👤 Charles W. Mcgary
- 👤 Vincent J. Pascarella
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 16:18
CPC Classifications
C; C08; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075; A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0029; A61L33/0047
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
54 words
An antithrombogenic polyurethane polymer which comprises: a polyurethare substrate; a polymeric amine covalently bonded to the polyurethane substrate; and an antithrombogenic agent covalently bonded to the polymeric amine; wherein the polymeric amine is chosen from: a polyvinyl amine, a polyalkylenimine which has 2, 3 or 4 carbon atoms per amine unit, and mixtures thereof.
Claim 2
Dependent Claim
54 words
An antithrombogenic polyurethane polymer which comprises: a polyurethare substrate; a polymeric amine covalently bonded to the polyurethane substrate; and an antithrombogenic agent covalently bonded to the polymeric amine; wherein the polymeric amine is chosen from: a polyvinyl amine, a polyalkylenimine which has 2, 3 or 4 carbon atoms per amine unit, and mixtures thereof.
Claim 3
Dependent Claim
26 words
An antithrombogenic polyurethane polymer accord ing to Claim 1, wherein the antithrombogenic agent is chosen from: heparin, prostaglandins, urokinase, streptokinase, sulphated polysaccharide, albumin and mixtures thereof.
Claim 4
Dependent Claim
26 words
An antithrombogenic polyurethane polymer according to Claim 1 or 2, wherein the polyurethane substrate is chosen from a thermosetting polyurethane polymer and a thermoplastic polyurethane polymer.
Claim 5
Dependent Claim
24 words
An antihrombogenic polyurethane polymer according to Claim 1, 2 or 3, wherein the polyalkylenimine is chosen from: polyethylenimine, polypropyl- enimine, polybutylenimine and mixtures thereof.
Claim 6
Dependent Claim
22 words
An antithrombogenic polyurethane polymer according to any preceding claim, wherein the polymeric amine has an average molecular weight of at least 11,000.
Claim 7
Dependent Claim
24 words
An antithrombogenic polyurethane polymer, according to any preceding claim, wherein the polymeric amine is covalently bonded to the polyurethane substrate by a polyisocyanate prepolymer.
Claim 8
Dependent Claim
26 words
An antithrombogenic polyurethane polymer according to Claim 6, wherein the polyisocyanate prepolymer contains from 2 to 30% free NCO units based upon the total NCO content.
Claim 9
Dependent Claim
36 words
An antithrombogenic polyurethane polymer according to any one of Claims 1 to 5, wherein the polymeric amine is covalently bonded to the polyurethane substrate through activated functional amine groups on the surface of the polyurethane substrate.
Claim 10
Dependent Claim
48 words
An antithrombogenic polyurethane polymer according to any preceding claim, wherein the antithrombogenic agent is activated with an activating agent to enable covalent coupling of the antithrombogenic agent to the polymeric amine, the activating agent preferably being chosen from: N-ethyl-5-phenyl- isoxazalium-3' -sulphonate, 1-ethy1-3-(3-dimethy1amino propyl) carbodiimide hydrochloride) and 1-cyclohexyl-3-(morpholinoethyl) carbodiimide.
Claim 11
Dependent Claim
107 words
A process for imparting antithrombogenic activity to a polyurethane substrate, which process comprises: (a) treating the surface of the polyurethane substrate with a solution of a polymeric amine to covalently bond the polymeric amine to the polyurethane substrate; (b) washing the surface to remove substantially all non-covalently bonded polymeric amine; and (c) treating the surface with an activated antithrombogenic agent to covalently bond the antithrombogenic agent to the polymeric amine; wherein the polymeric amine is chosen from a polyvinyl amine, a polyalkylenimine having 2 to 4 carbon atoms per amine unit and mixtures thereof; and wherein the pH of the polymeric amine solution is at least 5.0.
Claim 12
Dependent Claim
107 words
A process for imparting antithrombogenic activity to a polyurethane substrate, which process comprises: (a) treating the surface of the polyurethane substrate with a solution of a polymeric amine to covalently bond the polymeric amine to the polyurethane substrate; (b) washing the surface to remove substantially all non-covalently bonded polymeric amine; and (c) treating the surface with an activated antithrombogenic agent to covalently bond the antithrombogenic agent to the polymeric amine; wherein the polymeric amine is chosen from a polyvinyl amine, a polyalkylenimine having 2 to 4 carbon atoms per amine unit and mixtures thereof; and wherein the pH of the polymeric amine solution is at least 5.0.
Claim 13
Dependent Claim
23 words
A process according to Claim 10, in which an antithrombogenic polyurethane polymer according to any one of Claims 1 to 9 is prepared.
Claim 14
Dependent Claim
52 words
A process according to Claim 10 or 11, wherein the polymeric amine is covalently bonded to the polyurethane substrate through activated functional amine groups on the surface of the polyurethane substrate and wherein the activation of the polyurethane substrate is achieved by etching the surface of the polyurethane with concentrated hydrochloric acid.
Claim 15
Dependent Claim
32 words
A process according to any one of Claims 10, 11, or 12, wherein the pH of the polymeric amine solution is in the range from 5.0 to 12.0, preferably 7.0 to 9.0
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.